+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Novel Drug Delivery Systems Market by Route of Administration, Technology, Application, Product Type, End User - Global Forecast to 2030- Product Image
Novel Drug Delivery Systems Market by Route of Administration, Technology, Application, Product Type, End User - Global Forecast to 2030- Product Image
Sale

Novel Drug Delivery Systems Market by Route of Administration, Technology, Application, Product Type, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 182 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5666187
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Novel Drug Delivery Systems Market grew from USD 15.00 billion in 2024 to USD 16.40 billion in 2025. It is expected to continue growing at a CAGR of 9.31%, reaching USD 25.60 billion by 2030.

Pioneering the Future of Drug Delivery

Over the past decade, advances in materials science and bioengineering have primed the field of drug delivery for unprecedented breakthroughs. Novel systems that transcend the constraints of conventional administration are reshaping therapeutic paradigms and unlocking new frontiers in patient care.

The emergence of precision platforms-ranging from implantable pumps to nanoparticle carriers-addresses critical challenges in efficacy, safety, and adherence. By optimizing release profiles and targeting specific tissues, these technologies minimize off-target effects and enhance therapeutic indices.

Patient-centricity lies at the core of this transformation. Microneedle patches that enable painless self-administration, inhalable formulations that bypass first-pass metabolism, and smart hydrogels responsive to physiological cues exemplify a shift toward more convenient, compliant, and personalized regimens.

This executive summary presents a concise overview of the critical market dynamics, including transformative shifts, trade policy impacts, segmentation insights, regional trends, competitive benchmarks, actionable recommendations, and rigorous methodological underpinnings.

Shifting Paradigms in Therapeutic Administration

The landscape of therapeutic administration is experiencing seismic shifts driven by a convergence of digital health, advanced materials, and regulatory evolution. Integration of sensors and connectivity into delivery devices is transforming passive carriers into interactive platforms that monitor patient adherence in real time.

Artificial intelligence and machine learning are accelerating formulation discovery, enabling rapid screening of excipients and predicting pharmacokinetic profiles. This data-driven approach reduces time-to-market and enhances pipeline efficiency.

Regulatory bodies are adapting frameworks to accommodate these innovations, issuing guidance on combination products and digital therapeutics. Harmonization initiatives across major markets are fostering a more predictable environment for global launch strategies.

The growing emphasis on real-world evidence and value-based reimbursement models is compelling stakeholders to demonstrate not only clinical efficacy but also economic and patient-reported outcomes. This shift is catalyzing collaborative ventures between technology firms, pharmaceutical innovators, and healthcare providers.

Assessing the Ripple Effects of New U.S. Tariffs

Implementation of new U.S. tariffs in 2025 on specialty polymers, device components, and active pharmaceutical ingredients has exerted upward pressure on manufacturing costs. Suppliers reliant on affected imports have renegotiated contracts and adjusted product pricing, passing incremental expenses along the value chain.

Manufacturers are exploring alternative sourcing strategies, including near-shoring and regional partnerships, to mitigate exposure to levies. Investment in local production capabilities has accelerated, with several facilities repurposed to produce critical delivery system inputs.

Downstream effects are evident in procurement negotiations with payers and group purchasing organizations, which are demanding greater transparency around cost drivers. Organizations that proactively engaged in scenario planning and cost-modelling exercises have preserved margin integrity more effectively than those that reacted post-implementation.

Looking ahead, agility in trade policy monitoring and the ability to deploy flexible manufacturing architectures will be essential to navigate ongoing geopolitical uncertainties. Firms that leverage data analytics to forecast tariff impacts and optimize supply routes will secure competitive advantage.

Unveiling Critical Segmentation Dynamics

Inhalation, injectable, nasal, oral, and transdermal routes each present unique challenges and opportunities. Dry powder inhalers and nebulizers are redefining respiratory care through precision dosing, while intramuscular, intravenous, and subcutaneous formats continue to expand therapeutic options for chronic and acute conditions. Nasal drops and sprays offer rapid onset for CNS delivery, and oral capsules, liquids, and tablets remain foundational for systemic therapy. Transdermal gels and patches provide sustained release without the need for daily dosing.

Technological differentiation is paramount. Natural and synthetic hydrogels form bioresponsive matrices, whereas biodegradable and non-biodegradable implants secure localized drug release over extended periods. Coated, dissolvable, hollow, and solid microneedles enable minimally invasive administration, and dendrimers, liposomes, polymeric, and solid lipid nanoparticles facilitate targeted delivery. Cationic and stealth liposomes further refine biodistribution and payload protection.

Therapeutic applications span cardiovascular interventions with stents and transcatheter devices to endocrinology solutions for diabetes management and hormone replacement. Infectious disease platforms are tailored for antibiotic, antiviral, and vaccine delivery. Neurology strategies address both central and peripheral disorders, oncology systems optimize chemotherapy, immunotherapy, and targeted therapy, and ophthalmology leverages eye drops and ocular implants for localized treatment.

Depot injections in biodegradable and non-biodegradable formats, coronary and peripheral drug-eluting stents, infusion and osmotic pumps, conventional and stealth liposomal formulations, and dissolvable and solid microneedle patches represent the core product types. End-user channels encompass ambulatory care, clinics, home care settings, hospitals, and pharmacies, each demanding customized service models to support adoption and training.

Regional Hotspots Driving Delivery Innovations

The Americas lead in adoption of minimally invasive delivery platforms, driven by robust reimbursement frameworks and a mature manufacturing infrastructure that supports rapid scale-up. Close collaboration among regulatory agencies, academic centers, and device innovators fosters a fertile environment for pilot programs and early-stage clinical trials.

Europe, the Middle East, and Africa benefit from regulatory harmonization across EU member states, the Gulf Cooperation Council, and emerging economies in North Africa. Cross-border partnerships and consortiums are advancing combination products, while multilateral initiatives are streamlining approval pathways for complex biologics and companion devices.

Asia-Pacific markets are experiencing exponential growth as rising healthcare expenditures and expanding middle-class populations accelerate demand for cost-effective, patient-friendly delivery solutions. Strategic alliances with global technology providers and localized manufacturing investments are enabling rapid market entry and customization to regional epidemiological profiles.

Spotlight on Industry Trailblazers

Several established pharmaceutical and medical device companies are positioning themselves at the forefront of next-generation delivery. Johnson & Johnson’s recent alliance with a startup specializing in microneedle arrays underscores its commitment to pain-free vaccination platforms. Pfizer has channeled R&D funds into implantable pump technology for chronic pain management, signaling a strategic pivot toward sustained release solutions.

Novartis has expanded its portfolio through acquisition of a synthetic hydrogel specialist, integrating responsive biomaterials into its immunotherapy pipeline. Roche is leveraging its diagnostic expertise to develop companion devices that adjust dosing regimens based on real-time biomarker readings, exemplifying a seamless interface between therapy and monitoring.

Medtronic’s dual focus on infusion pumps and smart sensors reflects an integrated approach to diabetes care, while Becton Dickinson’s enhancements to injectable safety systems underscore ongoing efforts to improve user experience and compliance. Emerging players in nanoparticle engineering and bioresorbable implants are forging collaborations with global OEMs to accelerate commercialization.

These companies are also intensifying patent filings around novel excipients, device-drug interfaces, and software algorithms, reinforcing the critical intersection of IP strategy and first-mover advantage in this competitive arena.

Strategic Imperatives for Market Leadership

Leaders should prioritize investment in advanced R&D platforms that harness AI-driven modeling and high-throughput screening to accelerate formulation optimization. Establishing cross-functional centers of excellence will facilitate the translation of basic science innovations into scalable manufacturing processes.

Diversification of supply chains through near-shoring and multi-sourcing strategies is essential to mitigate trade policy risks and ensure consistent access to specialty materials. Strategic partnerships with regional contract manufacturers can bolster resilience and reduce lead times for critical components.

Early and proactive engagement with regulatory authorities will streamline approval workflows for combination products and digital therapeutics. Designing comprehensive clinical and real-world evidence strategies will pave the way for value-based discussions with payers and health systems.

Forming alliances with technology firms and academic institutions can expedite the development of integrated delivery-diagnostic solutions that enhance patient monitoring and adherence. Prioritizing sustainability by selecting eco-conscious materials and optimizing device lifecycles will meet evolving stakeholder expectations.

Finally, creating flexible commercialization models that encompass direct-to-consumer channels, telemedicine partnerships, and bundled service offerings will differentiate market positioning and drive long-term growth.

Robust Methodology Ensuring Rigorous Insights

This study integrates primary interviews with C-suite executives, formulation scientists, and manufacturing leaders to capture nuanced perspectives on innovation drivers and operational challenges. Supplemental surveys conducted across healthcare providers and patient advocacy groups provide firsthand insights into adoption barriers and unmet needs.

Extensive secondary research anchors the analysis in peer-reviewed literature, conference proceedings, patent filings, and publicly disclosed regulatory submissions. Financial reports and investor presentations offer additional context on capital allocation trends and competitive strategies.

Data triangulation methods ensure alignment between qualitative narratives and quantitative metrics, while sensitivity testing validates the robustness of segmentation definitions and market share estimations. Analytical models incorporate scenario planning to assess trade policy impacts, technology adoption curves, and region-specific growth vectors.

The resulting framework delivers actionable intelligence across five segmentation dimensions, three regional clusters, and a curated set of leading and emerging stakeholders. This rigorous methodology underpins strategic recommendations tailored to decision-makers seeking to navigate a dynamic and complex market environment.

Synthesis of Key Executive Takeaways

In summary, material innovations, regulatory evolution, and patient-centric design are converging to redefine drug delivery landscapes. Stakeholders equipped with granular segmentation insights, region-specific intelligence, and competitive benchmarks are poised to capitalize on emerging opportunities.

Navigating trade disruptions will require agile supply chain architectures, proactive policy engagement, and diversified sourcing strategies. Meanwhile, digital integration and evidence-based reimbursement models present pathways to enhance both clinical outcomes and economic value.

The strategic imperatives and actionable recommendations outlined herein offer a clear roadmap for leadership teams to transform challenges into sustainable growth levers. By aligning R&D, regulatory, and commercialization efforts, organizations can secure first-mover advantage in an increasingly competitive arena.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Route Of Administration
    • Inhalation
      • Dry Powder Inhalers
      • Nebulizers
    • Injectable
      • Intramuscular
      • Intravenous
      • Subcutaneous
    • Nasal
      • Drops
      • Sprays
    • Oral
      • Capsules
      • Liquids
      • Tablets
    • Transdermal
      • Gels
      • Patches
  • Technology
    • Hydrogels
      • Natural
      • Synthetic
    • Implants
      • Biodegradable
      • Nonbiodegradable
    • Microneedles
      • Coated
      • Dissolvable
      • Hollow
      • Solid
    • Nanoparticles
      • Dendrimers
      • Liposomes
        • Cationic Liposomes
        • Stealth Liposomes
      • Polymeric Nanoparticles
      • Solid Lipid Nanoparticles
  • Application
    • Cardiovascular
      • Stents
      • Transcatheter Devices
    • Endocrinology
      • Diabetes Management
      • Hormone Replacement
    • Infectious Diseases
      • Antibiotic Delivery
      • Antiviral Delivery
      • Vaccine Delivery
    • Neurology
      • CNS Disorders
      • Peripheral Disorders
    • Oncology
      • Chemotherapy
      • Immunotherapy
      • Targeted Therapy
    • Ophthalmology
      • Eye Drops
      • Ocular Implants
  • Product Type
    • Depot Injections
      • Biodegradable
      • Nonbiodegradable
    • DrugEluting Stents
      • Coronary
      • Peripheral
    • Implantable Pumps
      • Infusion Pumps
      • Osmotic Pumps
    • Liposomal Formulations
      • Conventional Liposomes
      • Stealth Liposomes
    • Microneedle Patches
      • Dissolvable
      • Solid
  • End User
    • Ambulatory Care
    • Clinics
    • Home Care
    • Hospitals
    • Pharmacies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Baxter International Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Novel Drug Delivery Systems Market, by Route of Administration
8.1. Introduction
8.2. Inhalation
8.2.1. Dry Powder Inhalers
8.2.2. Nebulizers
8.3. Injectable
8.3.1. Intramuscular
8.3.2. Intravenous
8.3.3. Subcutaneous
8.4. Nasal
8.4.1. Drops
8.4.2. Sprays
8.5. Oral
8.5.1. Capsules
8.5.2. Liquids
8.5.3. Tablets
8.6. Transdermal
8.6.1. Gels
8.6.2. Patches
9. Novel Drug Delivery Systems Market, by Technology
9.1. Introduction
9.2. Hydrogels
9.2.1. Natural
9.2.2. Synthetic
9.3. Implants
9.3.1. Biodegradable
9.3.2. Nonbiodegradable
9.4. Microneedles
9.4.1. Coated
9.4.2. Dissolvable
9.4.3. Hollow
9.4.4. Solid
9.5. Nanoparticles
9.5.1. Dendrimers
9.5.2. Liposomes
9.5.2.1. Cationic Liposomes
9.5.2.2. Stealth Liposomes
9.5.3. Polymeric Nanoparticles
9.5.4. Solid Lipid Nanoparticles
10. Novel Drug Delivery Systems Market, by Application
10.1. Introduction
10.2. Cardiovascular
10.2.1. Stents
10.2.2. Transcatheter Devices
10.3. Endocrinology
10.3.1. Diabetes Management
10.3.2. Hormone Replacement
10.4. Infectious Diseases
10.4.1. Antibiotic Delivery
10.4.2. Antiviral Delivery
10.4.3. Vaccine Delivery
10.5. Neurology
10.5.1. CNS Disorders
10.5.2. Peripheral Disorders
10.6. Oncology
10.6.1. Chemotherapy
10.6.2. Immunotherapy
10.6.3. Targeted Therapy
10.7. Ophthalmology
10.7.1. Eye Drops
10.7.2. Ocular Implants
11. Novel Drug Delivery Systems Market, by Product Type
11.1. Introduction
11.2. Depot Injections
11.2.1. Biodegradable
11.2.2. Nonbiodegradable
11.3. DrugEluting Stents
11.3.1. Coronary
11.3.2. Peripheral
11.4. Implantable Pumps
11.4.1. Infusion Pumps
11.4.2. Osmotic Pumps
11.5. Liposomal Formulations
11.5.1. Conventional Liposomes
11.5.2. Stealth Liposomes
11.6. Microneedle Patches
11.6.1. Dissolvable
11.6.2. Solid
12. Novel Drug Delivery Systems Market, by End User
12.1. Introduction
12.2. Ambulatory Care
12.3. Clinics
12.4. Home Care
12.5. Hospitals
12.6. Pharmacies
13. Americas Novel Drug Delivery Systems Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Novel Drug Delivery Systems Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Novel Drug Delivery Systems Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Johnson & Johnson
16.3.2. Pfizer Inc.
16.3.3. Novartis AG
16.3.4. F. Hoffmann-La Roche Ltd.
16.3.5. Merck & Co., Inc.
16.3.6. Sanofi S.A.
16.3.7. GlaxoSmithKline plc
16.3.8. AstraZeneca PLC
16.3.9. Becton, Dickinson and Company
16.3.10. Baxter International Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET MULTI-CURRENCY
FIGURE 2. NOVEL DRUG DELIVERY SYSTEMS MARKET MULTI-LANGUAGE
FIGURE 3. NOVEL DRUG DELIVERY SYSTEMS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 20. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. ASIA-PACIFIC NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. NOVEL DRUG DELIVERY SYSTEMS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 26. NOVEL DRUG DELIVERY SYSTEMS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. NOVEL DRUG DELIVERY SYSTEMS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRY POWDER INHALERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEBULIZERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NATURAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SYNTHETIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COATED, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOLLOW, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DENDRIMERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CATIONIC LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID LIPID NANOPARTICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSCATHETER DEVICES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DIABETES MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HORMONE REPLACEMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIBIOTIC DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ANTIVIRAL DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY VACCINE DELIVERY, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CNS DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY EYE DROPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OCULAR IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY BIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NONBIODEGRADABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CORONARY, BY REGION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFUSION PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OSMOTIC PUMPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CONVENTIONAL LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STEALTH LIPOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DISSOLVABLE, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY SOLID, BY REGION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 105. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 106. GLOBAL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 107. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 142. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 143. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 144. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 145. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 146. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 161. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 163. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 164. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 165. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 166. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 167. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 168. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 169. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 170. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 171. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 172. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 173. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 174. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 175. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 176. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 177. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 178. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 179. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 180. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 181. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 182. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 183. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 184. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 185. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 186. CANADA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 187. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 189. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 190. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 191. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 192. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 193. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 194. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 195. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 196. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 197. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 198. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 199. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 200. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 201. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 202. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 203. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 204. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 205. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 206. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 207. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 208. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 209. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 210. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 211. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 212. MEXICO NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 215. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 216. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 217. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 218. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 219. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 220. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 221. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 222. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 223. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 224. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 225. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 226. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 227. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 228. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 229. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 230. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 231. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 232. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 233. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 234. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 235. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 236. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 237. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 238. BRAZIL NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 239. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 240. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 241. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 242. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 243. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 244. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 245. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 247. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 248. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 249. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 250. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 251. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 253. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 254. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 255. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 256. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 257. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 258. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 259. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 260. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 261. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 262. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 263. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 264. ARGENTINA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 266. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 267. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 268. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 269. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 270. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 271. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 272. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 273. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 274. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 275. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 276. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 277. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 278. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 279. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 280. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 281. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 282. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 283. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)
TABLE 284. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 285. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DEPOT INJECTIONS, 2018-2030 (USD MILLION)
TABLE 286. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY DRUGELUTING STENTS, 2018-2030 (USD MILLION)
TABLE 287. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTABLE PUMPS, 2018-2030 (USD MILLION)
TABLE 288. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMAL FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 289. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLE PATCHES, 2018-2030 (USD MILLION)
TABLE 290. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. EUROPE, MIDDLE EAST & AFRICA NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 292. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INHALATION, 2018-2030 (USD MILLION)
TABLE 294. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
TABLE 295. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NASAL, 2018-2030 (USD MILLION)
TABLE 296. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ORAL, 2018-2030 (USD MILLION)
TABLE 297. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TRANSDERMAL, 2018-2030 (USD MILLION)
TABLE 298. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 299. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY HYDROGELS, 2018-2030 (USD MILLION)
TABLE 300. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY IMPLANTS, 2018-2030 (USD MILLION)
TABLE 301. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY MICRONEEDLES, 2018-2030 (USD MILLION)
TABLE 302. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NANOPARTICLES, 2018-2030 (USD MILLION)
TABLE 303. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY LIPOSOMES, 2018-2030 (USD MILLION)
TABLE 304. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 305. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY CARDIOVASCULAR, 2018-2030 (USD MILLION)
TABLE 306. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ENDOCRINOLOGY, 2018-2030 (USD MILLION)
TABLE 307. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2030 (USD MILLION)
TABLE 308. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY NEUROLOGY, 2018-2030 (USD MILLION)
TABLE 309. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 310. UNITED KINGDOM NOVEL DRUG DELIVERY SYSTEMS MARKET SIZE, BY OPHTHALMOLOGY, 2018-2030 (USD MILLION)

Companies Mentioned

The companies profiled in this Novel Drug Delivery Systems market report include:
  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Sanofi S.A.
  • GlaxoSmithKline plc
  • AstraZeneca PLC
  • Becton, Dickinson and Company
  • Baxter International Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages182
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 16.4 Billion
Forecasted Market Value ( USD ) by 2030 $ 25.6 Billion
Compound Annual Growth Rate9.3%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Buccal Drug Delivery Systems Market by Product Type, Drug Class, Application, End User, Distribution Channel - Global Forecast to 2030 - Product Image

Buccal Drug Delivery Systems Market by Product Type, Drug Class, Application, End User, Distribution Channel - Global Forecast to 2030

  • Report
  • 189 Pages
  • Global
From
Targeted Drug Delivery System Market by Therapeutic Application, Delivery Route, Technology, Drug Type, End User, Sales Channel - Global Forecast to 2030 - Product Image

Targeted Drug Delivery System Market by Therapeutic Application, Delivery Route, Technology, Drug Type, End User, Sales Channel - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Novel Drug Delivery Systems (NDDS) - Global Strategic Business Report - Product Image

Novel Drug Delivery Systems (NDDS) - Global Strategic Business Report

  • Report
  • 492 Pages
  • Global
From
Electronic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Electronic Drug Delivery Systems Market Size, Share & Trends Analysis Report By Product, By Application, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 120 Pages
  • Global
From
Hydrogel-based Drug Delivery Systems - Global Strategic Business Report - Product Image

Hydrogel-based Drug Delivery Systems - Global Strategic Business Report

  • Report
  • 290 Pages
  • Global
From

About the Novel Drug Delivery System Market

The Novel Drug Delivery System market is a subset of the larger Drug Delivery market. It focuses on the development and commercialization of new drug delivery systems, such as nanotechnology, gene therapy, and targeted drug delivery. These systems are designed to improve the efficacy of drugs, reduce side effects, and increase patient compliance. Novel Drug Delivery Systems are used to deliver drugs to specific sites in the body, such as the lungs, brain, and skin. They can also be used to deliver drugs to specific cells or tissues. The Novel Drug Delivery System market is driven by the increasing demand for more effective and safer drug delivery systems. This is due to the rising prevalence of chronic diseases, such as cancer, diabetes, and cardiovascular diseases. Additionally, the increasing focus on personalized medicine and the development of new technologies are expected to drive the market growth. Some of the major companies in the Novel Drug Delivery System market include Pfizer, Merck, Novartis, Johnson & Johnson, and Sanofi. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.